Search

» » Study finds Pfizer's antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week - MarketWatch

Study finds Pfizer's antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week - MarketWatch



Bagikan Berita Ini

0 Response to "Study finds Pfizer's antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week - MarketWatch"

Post a Comment

Subscribe to: Post Comments (Atom)
Powered by Blogger.